Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram
Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in p...
Gespeichert in:
Veröffentlicht in: | Journal of psychopharmacology (Oxford) 2012-05, Vol.26 (5), p.677-688 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 688 |
---|---|
container_issue | 5 |
container_start_page | 677 |
container_title | Journal of psychopharmacology (Oxford) |
container_volume | 26 |
creator | Stoy, Meline Schlagenhauf, Florian Sterzer, Philipp Bermpohl, Felix Hägele, Claudia Suchotzki, Kristina Schmack, Katharina Wrase, Jana Ricken, Roland Knutson, Brian Adli, Mazda Bauer, Michael Heinz, Andreas Ströhle, Andreas |
description | Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment. |
doi_str_mv | 10.1177/0269881111416686 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1020852937</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0269881111416686</sage_id><sourcerecordid>1020852937</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</originalsourceid><addsrcrecordid>eNqNkU2LFDEQhoMo7rh69yQBEby05vvjKIu6woIXPTe1mWrN0t1pk_Qs41_wT5thxg8WBOuSUO9Tb1VShDzl7BXn1r5mwnjneAvFjXHmHtlwZXhnhdP3yeYgdwf9jDwq5YYxbpTRD8mZ4F4YJeSG_LjcLykjhBp3se5pGugO55phpKXmCHWdaE23kLeFxjk0Ke6wSXFax9gydJ0n3MYAFbd0i0vGUtptgRobW-ic8gRj_I6FwlAx09qa1alp9DbWrxRLiBXGtGSYHpMHA4wFn5zOc_L53dtPF5fd1cf3Hy7eXHVBCVc7p6XSwoUWnllrteEaAgYjnfJCMY_eO-nkIJm8FugEoPFgwfOgJHIrz8nLo--S07cVS-2nWAKOI8yY1tJzJpjTwsv_QbmTyjLlGvr8DnqT1jy3h_RcKy-1UtY3ih2pkFMpGYd-yXGCvG9W_WGn_d2dtpJnJ-P1uv3174JfS2zAixMAJcA4ZJhDLH847ZWW5jBhd-QKfMG_pvtX45_eJbe6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1549354479</pqid></control><display><type>article</type><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</creator><creatorcontrib>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</creatorcontrib><description>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881111416686</identifier><identifier>PMID: 21926423</identifier><identifier>CODEN: JOPSEQ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antidepressive Agents, Second-Generation - therapeutic use ; Basal Ganglia - drug effects ; Basal Ganglia - physiopathology ; Biological and medical sciences ; citalopram ; Citalopram - therapeutic use ; Clinical outcomes ; Depression ; Depressive Disorder, Major - drug therapy ; Depressive Disorder, Major - physiopathology ; Female ; Functional magnetic resonance imaging ; Humans ; Information processing ; Intelligence ; Inventories ; Magnetic Resonance Imaging - methods ; Male ; Medical sciences ; Mental depression ; Mood disorders ; Motivation ; Neostriatum ; Neuroimaging ; Neuroimaging - methods ; Neuropharmacology ; NMR ; Nuclear magnetic resonance ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychotherapy ; Reinforcement ; Serotonin uptake inhibitors ; Serotonin Uptake Inhibitors - therapeutic use ; Smoking</subject><ispartof>Journal of psychopharmacology (Oxford), 2012-05, Vol.26 (5), p.677-688</ispartof><rights>The Author(s) 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Sage Publications Ltd. May 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</citedby><cites>FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881111416686$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881111416686$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25945368$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21926423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stoy, Meline</creatorcontrib><creatorcontrib>Schlagenhauf, Florian</creatorcontrib><creatorcontrib>Sterzer, Philipp</creatorcontrib><creatorcontrib>Bermpohl, Felix</creatorcontrib><creatorcontrib>Hägele, Claudia</creatorcontrib><creatorcontrib>Suchotzki, Kristina</creatorcontrib><creatorcontrib>Schmack, Katharina</creatorcontrib><creatorcontrib>Wrase, Jana</creatorcontrib><creatorcontrib>Ricken, Roland</creatorcontrib><creatorcontrib>Knutson, Brian</creatorcontrib><creatorcontrib>Adli, Mazda</creatorcontrib><creatorcontrib>Bauer, Michael</creatorcontrib><creatorcontrib>Heinz, Andreas</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Basal Ganglia - drug effects</subject><subject>Basal Ganglia - physiopathology</subject><subject>Biological and medical sciences</subject><subject>citalopram</subject><subject>Citalopram - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Depression</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Depressive Disorder, Major - physiopathology</subject><subject>Female</subject><subject>Functional magnetic resonance imaging</subject><subject>Humans</subject><subject>Information processing</subject><subject>Intelligence</subject><subject>Inventories</subject><subject>Magnetic Resonance Imaging - methods</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mood disorders</subject><subject>Motivation</subject><subject>Neostriatum</subject><subject>Neuroimaging</subject><subject>Neuroimaging - methods</subject><subject>Neuropharmacology</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychotherapy</subject><subject>Reinforcement</subject><subject>Serotonin uptake inhibitors</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Smoking</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU2LFDEQhoMo7rh69yQBEby05vvjKIu6woIXPTe1mWrN0t1pk_Qs41_wT5thxg8WBOuSUO9Tb1VShDzl7BXn1r5mwnjneAvFjXHmHtlwZXhnhdP3yeYgdwf9jDwq5YYxbpTRD8mZ4F4YJeSG_LjcLykjhBp3se5pGugO55phpKXmCHWdaE23kLeFxjk0Ke6wSXFax9gydJ0n3MYAFbd0i0vGUtptgRobW-ic8gRj_I6FwlAx09qa1alp9DbWrxRLiBXGtGSYHpMHA4wFn5zOc_L53dtPF5fd1cf3Hy7eXHVBCVc7p6XSwoUWnllrteEaAgYjnfJCMY_eO-nkIJm8FugEoPFgwfOgJHIrz8nLo--S07cVS-2nWAKOI8yY1tJzJpjTwsv_QbmTyjLlGvr8DnqT1jy3h_RcKy-1UtY3ih2pkFMpGYd-yXGCvG9W_WGn_d2dtpJnJ-P1uv3174JfS2zAixMAJcA4ZJhDLH847ZWW5jBhd-QKfMG_pvtX45_eJbe6</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Stoy, Meline</creator><creator>Schlagenhauf, Florian</creator><creator>Sterzer, Philipp</creator><creator>Bermpohl, Felix</creator><creator>Hägele, Claudia</creator><creator>Suchotzki, Kristina</creator><creator>Schmack, Katharina</creator><creator>Wrase, Jana</creator><creator>Ricken, Roland</creator><creator>Knutson, Brian</creator><creator>Adli, Mazda</creator><creator>Bauer, Michael</creator><creator>Heinz, Andreas</creator><creator>Ströhle, Andreas</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20120501</creationdate><title>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</title><author>Stoy, Meline ; Schlagenhauf, Florian ; Sterzer, Philipp ; Bermpohl, Felix ; Hägele, Claudia ; Suchotzki, Kristina ; Schmack, Katharina ; Wrase, Jana ; Ricken, Roland ; Knutson, Brian ; Adli, Mazda ; Bauer, Michael ; Heinz, Andreas ; Ströhle, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-8534528cccc907775615acec638492409e998383f303b2e82ae69a7a91c43e173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Basal Ganglia - drug effects</topic><topic>Basal Ganglia - physiopathology</topic><topic>Biological and medical sciences</topic><topic>citalopram</topic><topic>Citalopram - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Depression</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Depressive Disorder, Major - physiopathology</topic><topic>Female</topic><topic>Functional magnetic resonance imaging</topic><topic>Humans</topic><topic>Information processing</topic><topic>Intelligence</topic><topic>Inventories</topic><topic>Magnetic Resonance Imaging - methods</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mood disorders</topic><topic>Motivation</topic><topic>Neostriatum</topic><topic>Neuroimaging</topic><topic>Neuroimaging - methods</topic><topic>Neuropharmacology</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychotherapy</topic><topic>Reinforcement</topic><topic>Serotonin uptake inhibitors</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Smoking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stoy, Meline</creatorcontrib><creatorcontrib>Schlagenhauf, Florian</creatorcontrib><creatorcontrib>Sterzer, Philipp</creatorcontrib><creatorcontrib>Bermpohl, Felix</creatorcontrib><creatorcontrib>Hägele, Claudia</creatorcontrib><creatorcontrib>Suchotzki, Kristina</creatorcontrib><creatorcontrib>Schmack, Katharina</creatorcontrib><creatorcontrib>Wrase, Jana</creatorcontrib><creatorcontrib>Ricken, Roland</creatorcontrib><creatorcontrib>Knutson, Brian</creatorcontrib><creatorcontrib>Adli, Mazda</creatorcontrib><creatorcontrib>Bauer, Michael</creatorcontrib><creatorcontrib>Heinz, Andreas</creatorcontrib><creatorcontrib>Ströhle, Andreas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stoy, Meline</au><au>Schlagenhauf, Florian</au><au>Sterzer, Philipp</au><au>Bermpohl, Felix</au><au>Hägele, Claudia</au><au>Suchotzki, Kristina</au><au>Schmack, Katharina</au><au>Wrase, Jana</au><au>Ricken, Roland</au><au>Knutson, Brian</au><au>Adli, Mazda</au><au>Bauer, Michael</au><au>Heinz, Andreas</au><au>Ströhle, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>26</volume><issue>5</issue><spage>677</spage><epage>688</epage><pages>677-688</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><coden>JOPSEQ</coden><abstract>Major Depressive Disorder (MDD) involves deficits in the reward system. While neuroimaging studies have focused on affective stimulus processing, few investigations have directly addressed deficits in the anticipation of incentives. We examined neural responses during gain and loss anticipation in patients with MDD before and after treatment with a selective serotonin reuptake inhibitor (SSRI). Fifteen adults with MDD and 15 healthy participants, matched for age, verbal IQ and smoking habits, were investigated in a functional magnetic resonance imaging (fMRI) study using a monetary incentive delay task. Patients were scanned drug-free and after 6 weeks of open-label treatment with escitalopram; controls were scanned twice at corresponding time points. We compared the blood oxygenation level dependent (BOLD) response during the anticipation of gain and loss with a neutral condition. A repeated measures ANOVA was calculated to identify effects of group (MDD vs. controls), time (first vs. second scan) and group-by-time interaction. Severity of depression was measured with the Hamilton Rating Scale of Depression and the Beck Depression Inventory. MDD patients showed significantly less ventral striatal activation during anticipation of gain and loss compared with controls before, but not after, treatment. There was a significant group-by-time interaction during anticipation of loss in the left ventral striatum due to a signal increase in patients after treatment. Ventral striatal hyporesponsiveness was associated with the severity of depression and in particular anhedonic symptoms. These findings suggest that MDD patients show ventral striatal hyporesponsiveness during incentive cue processing, which normalizes after successful treatment.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>21926423</pmid><doi>10.1177/0269881111416686</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0269-8811 |
ispartof | Journal of psychopharmacology (Oxford), 2012-05, Vol.26 (5), p.677-688 |
issn | 0269-8811 1461-7285 |
language | eng |
recordid | cdi_proquest_miscellaneous_1020852937 |
source | Access via SAGE; MEDLINE |
subjects | Adult Adult and adolescent clinical studies Antidepressive Agents, Second-Generation - therapeutic use Basal Ganglia - drug effects Basal Ganglia - physiopathology Biological and medical sciences citalopram Citalopram - therapeutic use Clinical outcomes Depression Depressive Disorder, Major - drug therapy Depressive Disorder, Major - physiopathology Female Functional magnetic resonance imaging Humans Information processing Intelligence Inventories Magnetic Resonance Imaging - methods Male Medical sciences Mental depression Mood disorders Motivation Neostriatum Neuroimaging Neuroimaging - methods Neuropharmacology NMR Nuclear magnetic resonance Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychotherapy Reinforcement Serotonin uptake inhibitors Serotonin Uptake Inhibitors - therapeutic use Smoking |
title | Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T14%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyporeactivity%20of%20ventral%20striatum%20towards%20incentive%20stimuli%20in%20unmedicated%20depressed%20patients%20normalizes%20after%20treatment%20with%20escitalopram&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Stoy,%20Meline&rft.date=2012-05-01&rft.volume=26&rft.issue=5&rft.spage=677&rft.epage=688&rft.pages=677-688&rft.issn=0269-8811&rft.eissn=1461-7285&rft.coden=JOPSEQ&rft_id=info:doi/10.1177/0269881111416686&rft_dat=%3Cproquest_cross%3E1020852937%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1549354479&rft_id=info:pmid/21926423&rft_sage_id=10.1177_0269881111416686&rfr_iscdi=true |